Nucleic Acid Therapeutics is the leading journal in its field focusing on cutting-edge basic research, therapeutic applications, and drug development using nucleic acids or related compounds to alter gene expression. The Journal examines many new approaches for using nucleic acids as therapeutic agents or in modifying nucleic acids for therapeutic purposes including: oligonucleotides, gene modification, aptamers, RNA nanoparticles, and ribozymes.
Nucleic Acid Therapeutics is the Official Journal of the OTS. OTS members can access the Journal via the member website, and we encourage members to recommend the Journal to their library or institution to facilitate collaboration with colleagues.
The Journal is led by Co-Editors-in-Chief Bruce A. Sullenger, PhD and Annemieke Aartsma-Rus, PhD, Executive Editor Graham Parker, PhD, Senior Editors David Corey, PhD, Mark Kay, MD, PhD and Brett Monia, PhD, European Editor Jens Kurreck, PhD and Asian Editor Dong-ki Lee, PhD and other leading investigators. View the entire editorial board.
Read a free issue of Nucleic Acid Therapeutics online.
Submit your paper online today! Accepted papers are published online ahead of The Journal features rapid peer review and publication online within 6 weeks of acceptance, and offers Open Access options. Detailed information and instructions for authors is available online.
Latest Impact Factor: 2.929
2014 Journal Citation Reports® published by Thomson Reuters, 2015
Online Journal Access
Current members of the Oligonucleotide Therapeutics Society receive a complimentary online journal subscription to the society’s official journal, Nucleic Acid Therapeutics. Note that it takes between 1-2 weeks after purchasing your membership to receive your online login instructions, which come directly from the journal’s publisher, Mary Ann Liebert publishers, Inc.